Valerie Vanhooren

Valerie Vanhooren is the Co-founder and Chief Executive Officer of ONA Therapeutics, a biotechnology company focused on developing innovative treatments for advanced cancers.13 She has been leading the company since its founding in 2019, guiding the growth and development of ONA's pipeline of first-in-class antibody-drug conjugates (ADCs) and antibodies.1

Professional Background

Valerie has extensive experience in the biotech industry, particularly in the discovery and development of antibodies and protein conjugates for oncology.1 Her career highlights include:

• ONA Therapeutics: Co-founder and CEO since May 20192
• ProteoDesign: Director of R&D and Project Leader (2017-2019)2
• Intelligent Pharma: Business Development and Project Manager (2016-2017)2
• Ablynx: Project Leader/Planner (2014-2016)2

Education and Research

Valerie holds a PhD in Biotechnology from the University of Ghent, Belgium.1 Her academic background also includes:

• Postdoctoral research at VIB (Flanders Institute for Biotechnology) from 2010 to 20132
• Postdoctoral stay at IRB Barcelona from 2012 to 20132

Achievements at ONA Therapeutics

Under Valerie's leadership, ONA Therapeutics has:

• Secured over 35 million euros from international investors and non-dilutive grants1
• Developed a pipeline focusing on two wholly owned internal programs, including a first-in-class antibody drug conjugate for refractory breast cancer3
• Been recognized as one of Fierce Biotech's "Fierce 15" Biotech Companies of 20203

Valerie's expertise in drug development and collaborative partnerships with pharmaceutical entities has been instrumental in ONA Therapeutics' growth and success in the field of advanced cancer therapeutics.